Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ABBV crawled date : 2021 - 12 - 13 save search
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 positive bioscience results
Aesthetic Lasers and Energy Devices Market to grow by USD 861.45mn|Evolving Opportunities with AbbVie Inc. & Bausch Health Companies Inc.| 17000+ Technavio Reports
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: -1.93%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
health aesthetic device energy laser
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.